INS360 is a set of guidelines (recommended here for the first time) for the selection (or equally importantly de-selection) and progression of ADEV compounds. The simple idea behind this is to generate a comprehensive informatics profile around the compoundtarget -disease axis that is central to the project (hence in silico 360). This would primarily be achieved using databases and prediction tools encompassing (but not restricted to) cheminformatics, bioinformatics, genomics, data mining and literature searching. The advantages of INS360 are  The project team will have starting points already  Being low-cost compared with lab work  Faster execution than experimentation  Presents decision-support checkpoints before further resource commitment  It is hypothesis-neutral in the propensity to garner both good news on potential efficacy as well as bad news regarding chemistry-specific or target-specific liabilities  Relevant data sources are expanding in content by the month  Analyses can be pipelined and parallelised to support multiple projects  AI/ML approaches are becoming applicable to some of the operations  Much can be done with public databases but there are synergies with commercial sources  The production of a "due diligence" package is essential to convince stakeholders, funders and potential collaborators  The learning gains from this can change direction of a project and is immediately transferable to new ones While there are no associated disadvantages, INS360 presents the challenge of effectively supporting an ADEV team (and the stakeholders thereof) with a broad range of advanced informatics that conform to at least some level of systematic best-practice. The imperative for this is generally underappreciated even when highly competent teams have impressive experimental track records by which they have achieved lead compounds with potent and selective in vitro target modulation. We can illustrate the challenges with some examples;